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Abstract 
Glaucoma is a multifactorial neurodegenerative disorder and one of the leading causes 
of irreversible blindness globally and for which intraocular pressure is the only 
modifiable risk factor. Although neuroprotective therapies have been suggested to have 
therapeutic potential, drug delivery for the treatment of ocular disorders such as 
glaucoma remains an unmet clinical need, further complicated by poor patient 
compliance with topically applied treatments. In the present study we describe the 
development of multi-loaded PLGA-microspheres (MSs) incorporating three recognised 
neuroprotective agents (dexamethasone (DX), melatonin (MEL) and coenzyme Q10 
(CoQ10)) in a single formulation (DMQ-MSs) to create a novel sustained-release 
intraocular drug delivery system (IODDS) for the treatment of glaucoma. MSs were 
spherical, with a mean particle size of 29.04 ± 1.89 μm rendering them suitable for 
intravitreal injection using conventional 25G-32G needles.  Greater than 62% 
incorporation efficiency was achieved for the three drug cargo and MSs were able to 
co-deliver the encapsulated active compounds in a sustained manner over 30-days 
with low burst release. In vitro studies showed DMQ-MSs to be neuroprotective in a 
glutamate-induced cytotoxicity model (IC50 10.00±0.94 mM versus 6.89±0.82 mM in 
absence of DMQ-MSs) in R28 cell line. In vivo efficacy studies were performed using a 
well-established rodent model of chronic ocular hypertension (OHT), comparing single 
intravitreal injections of microspheres of DMQ-MSs to their equivalent individual single-
drug loaded MSs mixture (MSsmix), empty MSs, no-treatment OHT only and naïve 
groups. Twenty one days after OHT induction, DMQ-MSs showed a significantly 
neuroprotective effect on RGCs compared to OHT only controls. No such protective 
effect was observed in empty MSs and single-drug MSs treated groups. This work 
suggests that multi-loaded PLGA MSs present a novel therapeutic approach in the 
management of retinal neurodegeneration conditions such as glaucoma.  
Keywords: Intraocular Drug Delivery, Poly lactic-co-glycolic acid (PLGA), 
Neuroprotection, In vivo efficacy, Glaucoma, Co-delivery, Combination therapy 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
4 
 
 
1. Introduction 
 
Glaucoma is a multifactorial neurodegenerative disorder and one of the leading causes 
of irreversible blindness worldwide [1]. While this condition is primarily characterised by 
the loss of retinal ganglion cells (RGCs) and the gradual degeneration of RGC axons in 
the optic nerve [2], recent morphological and functional studies have suggested the 
involvement of other retinal cell types, including atrophic changes in the photoreceptor 
layer and microglia activation [3-5]. At present, intraocular pressure (IOP) is the major 
clinically modifiable risk factor for glaucoma progression (vision loss) and current 
therapies seek to modulate IOP via reducing aqueous production or increasing outflow 
[6]. With the recognition that glaucoma patients can continue to progress despite well 
controlled IOP, new therapeutic paradigms for the treatment of this condition are being 
sought [7, 8]. One such approach is neuroprotection which is defined as a “therapeutic 
approach” aiming to directly prevent, hinder and, in some cases, reverse neuronal cell 
damage.[9] In glaucoma, this translates to non-IOP-dependent treatments that reduce 
the rate of RGCs loss and therefore preserve vision [10, 11].  To date, multiple 
neurodegenerative processes have been implicated in glaucomatous RGC loss, 
including: glutamate excitotoxicity, inflammation, mitochondrial dysfunction, oxidative 
stress, aggregation of misfolded proteins, neurotrophic deprivation, ischemia and 
axonal transport dysregulation [12-14]. Moreover, it is becoming clear that these events 
can interact and compound, suggesting that effective treatment of glaucoma may 
require a multi-modal approach [15, 16].  
 
At present, the majority of glaucoma therapies are administered topically as eye drops; 
however, poor ocular penetration of topically applied drugs to the posterior ocular 
segment combined with variable patient compliance limit the utility of this approach[17].  
Intraocular injection overcomes both these aspects, but this method of administration is 
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invasive, expensive, burdensome to deliver and associated with small though 
significant risks of complications[18]. Moreover, the short half-life values of the active 
substances in the vitreous makes necessary the use of repeated intravitreal 
injections[19]. Depending on the size, intraocular drug delivery system (IODDS) are 
classified as nanocarriers (1–1000 nm), microcarriers (1–1000 μm), and implants (>1 
mm).  The choice of the most convenient IODDS depends on the target site, the 
ophthalmic disease and the duration of the treatment. While implants and microcarriers 
have received a lot of interest because they can provide long-term delivery of the active 
substance, nanocarriers have the advantage to be internalised by cells being highly 
useful for gene therapy [20]. IODDS based on biodegradable particulate carrier 
systems have been extensively investigated for the sustained release of therapies to 
address these problems. Poly(lactide-co-glycolide) acid (PLGA) is approved by the 
FDA and European Medical Agency for use in intraocular devices [17, 21]. Among the 
different IODDS, microspheres (MSs) have recently gained considerable attention for 
ocular applications [22]. These controlled-release drug microsystems can be 
administered as suspensions using conventional 25G-32G needles. Moreover, 
repeated administration is reduced as IODSS can sustain therapeutic drug 
concentrations in target tissues for extended periods [20]. IODDS can additionally be 
used to personalize therapy by titrating the amount of administered MSs with individual 
need. The authors postulate that the employment of physical mixtures of different drug 
loaded-MSs would enable the treatment of more than one therapeutic target 
simultaneously. A recent published study from our group, however, reported that there 
is an upper limit to the amount of MSs that can be injected intravitreally; 0.5 mg of 
PLGA-MSs was found to induce retinal stress and photoreceptor dysfunction in 
rodents, a phenomenon not observed on administration of 0.1 mg of MSs [23]. To 
reduce the amount of carrier administered, we have since developed MSs co-delivery 
systems able to incorporate and control the release of multiple active substances from 
a single carrier[24]. 
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The present study describes a MSs formulation incorporating three established 
therapies with anti-inflammatory and neuroprotective activity; dexamethasone, 
melatonin and coenzyme Q10. The corticosteroid dexamethasone (DX) is commonly 
used in the treatment of ocular inflammation in conditions such as diabetic macular 
edema, central retinal vein occlusion, and uveitis [25-27]. Melatonin (MEL) is an 
antioxidant with free radical scavenging and neuroprotective activity mediated via 
multiple mechanisms including the inhibition of the mitochondrial transition pore, 
reducing NO-induced apoptosis or reducing excitotoxicity Ca2+ overload [28-31]. 
Coenzyme Q10 (ubiquinone, CoQ10), an essential cofactor of the electron transport 
chain, is known for its key role in mitochondrial bioenergetics by maintaining the 
membrane potential, supporting ATP synthesis and inhibiting reactive oxygen species 
generation [32-36].   
In the present work, we sought to evaluate the effect of a MSs drug co-delivery system 
(DX, MEL and CoQ10) vs an equivalent physical mixture of single drug loaded MSs on 
RGC survival using the well-established Morrison’s rodent model of ocular 
hypertension. In vivo study sought to produce, characterise and evaluate the ability of 
novel combinations of established neuroprotective therapies to preserve RGC 
populations. Endpoints in this study included in vitro cell viability and whole-retinal 
histological assessments of RGC population. The in vitro neuroprotective activity of 
DMQ-MSs formulations were assessed using an in vitro glutamate-mediated 
neurotoxicity model in an immortalised and rat derived neuronal cell line (R28)[37]. 
While induction of the Morrison’s rodent model requires advanced microsurgical skills, 
it yields the following advantages compared to episcleral vein ligation models, 
including: (i) the establishment of anterior chamber deepening consistent with aqueous 
humor outflow obstruction, something not observed in episcleral vein ligation 
models.[38], (ii) reduced rate of IOP elevation [39], and (iii) reduced risk of ischemic 
injury[38].  
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To the authors knowledge, this is the first co-delivery study of three neuroprotective 
active substances in an IODDS administered to the posterior ocular segment. 
 
2. Materials and methods 
Dexamethasone, melatonin and coenzyme Q10 were supplied by Sigma-Aldrich (St. 
Louis Mo., USA) at the highest available purity. Poly(D,L-lactide-co-glycolide) (PLGA) 
50:50 (Mwt 35,000 g/mol) was purchased from Evonik España (Granollers, Spain). 
Polyvinyl alcohol 67,000 g/mol (PVA) was supplied by Merck KGaA (Darmstadt, 
Germany). Isopropyl alcohol, methanol and acetonitrile, HPLC grade (PanReac 
AppliChem, Barcelona, Spain) were used to prepare the mobile phases in HPLC 
determinations. All other chemicals were reagent grade and used as received.  
 
2.1 Manufacture of PLGA Microspheres  
PLGA microspheres (MSs) containing three neuroprotective agents (dexamethasone 
(DX), melatonin (MEL) and coenzyme Q10(CoQ10), 2/1/0.5:10) (DMQ-MSs) were 
prepared by the Oil/Water emulsion solvent extraction-evaporation technique (Fig.1). 
Briefly, CoQ10 (20 mg) and PLGA (400mg) were first dissolved in 0.7 mL of methylene 
chloride. 80 mg DX and 40 mg MEL were then ground in a pestle and mortar before 
dispersing in the organic PLGA solution by ultrasonication in an ice-water bath 
(Ultrasons; J.P. Selecta, Barcelona, Spain) for 5 minutes, followed by sonication 
(Sonicator XL; Heat Systems, Inc., Farmingdale, NY, USA) for 1 minute at 4 °C. Finally, 
the resulting organic phase was emulsified with 5 mL of polyvinyl alcohol (PVA) MiliQ 
water solution (1% w/v) in a homogenizer (Polytron®RECO, Kinematica, GmbHT 
PT3000, Lucerna, Swithzerland, 8,500rpm for 2 min). The first emulsion was then 
combined with 100 mL of an aqueous PVA solution (0.1%w/v) with magnetic stirred for 
3 hours at room temperature to facilitate organic solvent evaporation. After maturation, 
the formed MSs were washed in distilled water to remove PVA and separated 
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according to their particle size (38-20 µm) by filtration using two sieves (mesh size: 38 
and 20 µm). Finally, MSs were lyophilised (Freezing: -60oC /15 min, Primary drying: -40 
oC/12h/0.1 mBar, Secondary drying: 20 oC/2h/0.1 mBar) and resulting cakes stored at -
20 
o
C under dry conditions until required. In addition, MSs loaded with each single drug 
DX: PLGA (2:10), MEL:PLGA (1:10) and CoQ10:PLGA (0.5:10) and empty MSs in the 
absence of drug cargo were prepared using the same protocol. 
 
Figure 1. Elaboration process of the mullti -loaded MSs. 
 
 
2.2. Dexamethasone/melatonin/coenzyme Q10 quantification by LC/MS 
 
The LC/MS system comprised a Waters LC instrument (Waters 2707 autosampler and 
Waters 1525 binary HPLC pump) with a Nova-Pak C18 column (4μm, ID 2.1 mm×150 
mm) with a C18 guard column (3.9 mm ×20 mm), connected to a Waters 3100 single 
quadrupole mass spectrometer via Empower 2 (Waters, Milford, USA). The analytical 
column temperature was maintained at 45 ˚C. For MSs detection, the ESI source was 
operated in the positive ion mode (ESI(+)). Selected ion recordings (SIR) CoQ10 mass 
(m/z) 197, MEL mass (m/z) 174.2 and DX masses (m/z) 393.40 and 147.10 were 
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obtained with the following mass spectrometer source conditions of 3.5 kV electrospray 
voltage and 130 °C heated capillary temperature. Nitrogen gas (>99.999%) was used 
for nebulization (100 L/h flow rate, 130 °C source temperature, 5 V extractor voltage) 
and desolvation (400 L/h flow rate, 300 °C desolvation temperature). 
Two different isocratic HPLC methods were developed to quantify drug entrapment 
efficiencies (method A) and drug release from MSs (method B). Method A was 
composed of 50% of 10 mM ammonium acetate/1mL formic acid in methanol and 50% 
of 10 mM ammonium acetate/1mL formic acid in isopropyl alcohol (flow rate, 0.3 
mL/min) and method B 60% of 10 mM ammonium acetate/1mL formic acid in water 
and 40% of acetonitrile (flow rate, 0.3 mL/min).  
 
2.3. Microspheres characterization 
MSs were characterised in terms of production yield (%), mean particle size and size 
distribution, morphological evaluation, encapsulation efficiency, in vitro release studies 
and DSC Analysis. 
2.3.1. Production yield percentage 
 
The yield percentage (PY%) of each batch was calculated according to the following 
equation (1): 
PY % =
Weight of MSs (W1)
Total weight of active substances and polymer (W2)
 x 100 
          [Eq.1] 
 
2.3.2. Mean particle size and particle size distribution 
Particle size and the particle size distribution was measured by light scattering 
Microtrac® S3500 Series Particle Size Analyzer, Montgomeryville, PA, USA). The mean 
particle sizes, expressed as volume mean diameters, and standard deviation were 
determined. Each sample was run in triplicate. 
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2.3.3. Morphological evaluation 
 
The external morphology of the freeze-dried microspheres was observed by scanning 
electron microscopy (SEM, Jeol, JSM-6335F, Tokyo, Japan). Samples were gold 
sputter-coated prior to observation. The internal morphology of MSs was examined 
using thickness slides (70 nm) of cross-section by transmission electron microscopy 
(TEM, Jeol, JEM-1010, MA, USA). A Leica Cryostat CM 1900 was employed to create 
the cross-sections of microspheres at -20 0C placed into a synthetic resin medium 
(Spurr Low Viscosity Embedding Kit).   
 
2.3.4. Encapsulation efficiency 
 
The determination of the drug entrapment efficiencies was quantified as follows: 1 mg 
of MSs was dissolved in 2.5 mL of methylene chloride, following which drugs were 
extracted with methanol (6 mL), which also promoted polymer precipitation. After vortex 
mixing, the samples were centrifuged (5,000rpm for 5 minutes at 20ºC) and the 
methanolic supernatant was recuperated and filtered (0.22µm). High-Performance 
Liquid Chromatography-mass spectrometry (HPLC-MS) was employed for active 
substance quantifications according to the method described previously (Method A).  
 
2.3.5. In vitro release studies 
 
5 mg of MSs (DX-loaded MSs, MEL-loaded MSs and DMQ  
(Dexamethasone/Melatonin/Coenzyme Q10)-loaded MSs) were suspended in 2 mL of 
release medium (phosphate buffer saline (PBS, pH 7.4) with sodium azide (0.02%)) in 
duplicate and placed in a water shaker bath under constant agitation (100 rpm) at 37ºC 
(Memmert Shaking Bath, Memmert, Schwabach, Germany). At specified timepoints (1, 
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2, 4, 7, 10, 14, 17, 21, 24, 28 and 30 days) samples were centrifuged (5,000 rpm for 5 
min, 20ºC) and the supernatants removed and replaced by the same volume of fresh 
media. After filtration (0.22μm), drug concentrations in the release media were 
measured by LC/MS, according to the aforementioned method. 
 
Due to the poor aqueous solubility of CoQ10, the release profile of this drug was 
determined as the difference between initial encapsulation efficiency and the 
concentration remaining incorporated within the MSs at each sampling time. Here, 22 
samples of CoQ10-loaded MSs and DMQ-loaded MSs (4mg) were suspended in 2 mL 
of release medium and kept under a constant agitation at 37ºC. At the specified time 
points MSs suspensions were centrifuged (8,500 rpm; 3 min; 20 ºC) and the 
supernatants removed, and particles freeze-dried. Subsequently, the amount of CoQ10 
was quantified according to the aforementioned encapsulation efficiency method.  
 
2.3.6. DSC Analysis 
 
Thermal analysis of starting materials, empty and drug loaded MSs were carried out by 
means of a Mettler differential scanning calorimeter (DSC820, Toledo Mettler 
Laboratory & Weighing Tech., Greifensee, Suiza) equipped with a TAC 7/DX 
instrument controller. A STAR
e
 SW9.10 system software was used for the data 
acquisition. A heating rate of 10 ºC/min in heating-cooling-heating cycle (25-100ºC/100-
25ºC/25-280ºC temperature ranges) was employed and an empty aluminium pan 
(Mettler) was used as a reference standard. Analysis were performed on 5 mg samples 
under nitrogen purge. 
 
2.4. Cell culture  
R28 cell line (Kerafast, Boston, MA) was cultured in Dulbecco's modified Eagle's 
medium (DMEM; Invitrogen, Paisley, UK) supplemented with 5% heat-inactivated foetal 
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bovine serum (Invitrogen, UK), 100 U/ml penicillin, 100μg/ml of streptomycin and 0.292 
mg/mL glutamine (Gibco, UK), 7.5% sterile dH20 and 1.5 mM KCl (Sigma-Aldrich, UK). 
Cells were maintained under standard conditions: 37ºC, 5% CO2, 100% humidity, 
medium was changed completely every other day and cultures were passaged at 90% 
confluence. 
 
 
2.4.1. Cell viability assessment 
 
R28 cells were seeded at 4,000 cells/well in 96-well plates for 24 h before treatment 
with varying concentrations of the three active substances (DX, MEL, CoQ10), 
individually or in the form of a multiloaded MSs formulation and appropriate vehicle 
controls for a second 24h period. During this second 24h period, cells were additionally 
exposed to varying concentrations of the cytotoxic insult Glutamate (Sigma-Aldrich, 
UK). After this time, cell viability in the presence/absence of each therapy and insult 
was assessed by Alamarblue (Invitrogen, UK) assay according to manufacturer’s 
instructions. Briefly, the Alamarblue solution (10% v/v) was added to each well and 
incubated for 4 h at 37 °C. A Safire plate reader (excitation of 530 nm and emission of 
590 nm) was used for the fluorescence measurement and determination of percentage 
cell viability as previously described [36]. All experiments were completed in triplicate. 
 
2.5. Animals  
Adult male Dark Agouti (150-200g, Harlan Laboratories, UK) rats were housed in a 
temperature (21ºC) and humidity-controlled environment with a 12 h light-dark cycle 
(140–260 lux). Water and food were available ad libitum. All procedures described 
were performed in agreement with the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research and under protocols approved by the U.K. Home 
Office. 
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2.5.1. Ocular hypertension model 
IOP elevation was performed in the left eyes of twenty-five Dark Agouti rats by 
episcleral injection of hypersaline solution as previously described (Morrison’s ocular 
hypertension model)[40]. On the day of glaucoma induction, IOP measurements were 
performed in both eyes with a TonoLab tonometer (Tiolat Oy, Helsinki, Finland). 
Subsequently, the animals received general anesthesia using a mixture of 37.5% 
Ketamine (Pfizer Animal Heath, Exton, PA), 25% Dormitol (Pfizer Animal Heath, Exton, 
PA) and 37.5% sterile water, at 2 mL/kg administered intraperitoneally. To elevate the 
IOP, a syringe pump (50μL/min; UMP2; World Precision Instruments, Sarasota, FL, 
USA) was used to inject 50 µL of hypertonic saline solution (1.85 M) into the two 
episcleral veins. A propylene ring with a 1 mm gap cut from the circumference was 
placed around the equator to prevent injected saline outflow from other aqueous veins. 
Once a week, the IOP from both eyes of each rat was measured at regular intervals 
using a TonoLab tonometer (Tiolat Oy, Helsinki, Finland) under inhalational 
anaesthesia (0.4% isoflurane inoxygen) until 21 days post unilateral IOP elevation. For 
each animal, cumulative IOP exposure, defined as the integral of IOP elevation over 
time (mm Hg/day), was calculated from the area under the curve, as previously 
described[41].  
 
2.5.2. Microspheres administration 
Animals were randomized into 5 treatment groups (n = 5 each): non-loaded PLGA MSs 
(Empty-MSs, 5.825% w/v), multiloaded MSs (DMQ-loaded MSs, 2.5% w/v), the 
physical mixture of each single drug loaded MSs (DX-loaded MSs, MEL-loaded MSs 
and CoQ10-loaded MSs, MSsmix, 5.825% w/v), OHT-untreated and naïve controls 
(Table 1).  
Table 1 
Suspensions of administered MSs  
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 DMQ-loaded MSs 
Physical Mixture of MSs 
Empty-MSs 
DX-MSs  MEL-MSs  CoQ10-MSs  
AMOUNT OF MSs (mg) 
 0.071 0.082 0.08  
0.1 
 
0.233 
 
0.233 
DOSES (µg drug) 
DX / MEL /CoQ10 
11.5 / 4.6 / 3.6 
      DX                   MEL                CoQ10 
     11.5                   4.6                    3.6 
- 
VOL. INYECTED (µL) 4 4 4 
 MSs suspension (w/v) % 2.5 5.825 5.825 
 
 
The amount of MSs loaded with each single drug injected in the physical mixture was 
calculated in order to administer the same dose of the active substances (DX, MEL and 
CoQ10) included in the multiloaded formulation. Similarly, the amount of MSs in the 
Empty-MSs was equivalent to the highest dose of MSs injected.  
 
Homogeneous suspensions of MSs were prepared in PBS and briefly vortexed 
immediately prior to each injection. Intravitreal injections of microspheres were 
administered under general anaesthesia and aseptic conditions before IOP elevation 
surgery in left eyes of 15 rats, with no treatment given to 5 OHT-only and 5 bilaterally 
naïve animals.  
 
A 30-gauge hypodermic needle was used to perforate the sclera 1.5 mm behind the 
limbus. Four microliters of sample were then injected into the vitreous using a 5 μL 
Hamilton Syringe (Hamilton Co, Reno, NV). To prevent backflow of MSs, the needle 
was left in place for a short while and withdrawn slowly. Animals were euthanized 23 
days post-surgery. 
 
2.5.3 Brn3a immunohistochemistry and confocal microscopy 
After animals were sacrificed, enucleated eyes were fixed in 4% paraformaldehyde at 
4ºC overnight before dissecting retinal whole mounts. Brn3a+ RGCs were labelled as 
previously described [41]. Briefly, RGCs were labelled using an anti-mouse mAb 
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(1:750; Merk Milipore, Darmstadt, Germany) and as secondary detection donkey anti-
mouse IgG(HbL)-Alexa 647 (1:200; Merk Milipore, Darmstadt, Germany). 
Subsequently, retinas were examined under confocal microscopy (LSM 710; Carl Zeiss 
MicroImaging GmbH, Jena, Germany). Whole-mounts were imaged as a tiled z-stack 
at ×10 magnification, which was used to generate a single plane maximum projection 
of the RGC layer in each retina for subsequent analysis. Each whole-mount image was 
manually orientated so that the superior retina was towards the top of the image using 
in vivo cSLO imaging of retinal vasculature as a reference. Retina image acquisition 
settings were kept constant for all retinas imaged, allowing comparison of Brn3a 
expression in each experimental group as previously described [42]. Automated 
quantification of Brn3a labelled RGCs in retinal whole mounts was completed as 
described previously [41]. 
2.6. Statistical analysis 
All data were represented as mean ± standard deviation (SD) or mean ± standard error 
(SE). Linear regression analysis was completed using R version 3.3.1. P < 0.05 was 
considered statistically significant.  
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3. Results  
 
3.1. Microspheres characterization 
SEM investigation confirmed the presence of spherical particles with comparable and 
regular size distributions. Surface morphological differences was observed between 
formulations. Non-loaded MSs, MEL-loaded MSs and DX-loaded MSs had a smooth 
appearance with only small imperfections visible in the case of loaded MSs. In contrast, 
CoQ10-loaded MSs exhibited a number of small pores with a rough surface. The 
microspheres formulation prepared with the three active compounds (DMQ-loaded 
MSs) showed similar porous and rough surfaces (Fig.2). 
TEM images of the fractured microspheres revealed a non-interconnected pore 
architecture inside the internal polymeric matrix. Compared to non-loaded MSs, the 
formulations loaded with actives substances presented big hollows in the inner 
structure. Thus, DX-loaded MSs inner structure showed solid particles consistent with 
dexamethasone crystals. MEL-loaded MSs presented a homogeneous porous 
composition whereas CoQ10-loaded MSs showed irregularly distributed large pores. 
The internal appearance of DMQ-loaded MSs revealed a combination of all three 
aspects (Fig.2). 
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Figure 2. Morphological evaluation (Scanning electron microscopy and Transmission electron 
microscopy) and particle size distribution. 
 
The MSs microencapsulation technique led to a high production yield (> 72% in all 
cases) with mean particle for the multiloaded and single loading formulations ranging 
from 24 to 29 μm as outlined in Table 2. 
 
3.1.1 Encapsulation efficiency 
Table 2 summarizes the encapsulation efficiency data for each formulation. DX 
encapsulation efficiency in the multiloaded MSs (78.20 ± 0.42 %) was reduced 
compared to the single one drug formulation (97.49 ± 1.53 %) suggesting some 
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competition for drug loading sites. In contrast, MEL and CoQ10 encapsulation 
efficiencies remained the same values in both formulations (~62% and ~96% 
respectively).  
 
 
 
 
 
 
 
 
3.1.2. Release studies  
Currently, the drug delivery research is focused on developing systems enable to 
maintain drug concentrations above the minimum effective level and below the 
maximum safe concentration for an extended period of time [43, 44]. Thus, the ultimate 
goal of the development of IODDS for the treatment of retinal diseases and other 
intraocular pathologies is to obtain long-acting injectable drug formulations with specific 
control of the release rate and a sustained effect into the target tissue [19, 45]. In the 
present work, the three active agents were released in vitro from the developed 
formulations in a controlled fashion up to the end of the assay (30 days). 
Figure 3 presents the release profile of each single loaded formulation (3A-C) and the 
release profile of each drug in the DMQ loaded MSs (3D). In the single loaded 
particles, the amount of dexamethasone in vitro released from DX-loaded MSs during 
the first 24 h (burst) represented 1.83 ± 0.06 % (2.97 ± 0.05 μg DX/mg MSs) of the 
encapsulated drug. After this low initial delivery, a sustained delivery was observed, 
with a release rate of 0.26 ± 0.02 μg DX/mg MSs/day from day 1 to day 24, increasing 
to 1.64 ± 0.30 μg DX/mg MSs/day from day 24 to day the end of the study (day 30) (Fig 
Table 2 
Production yield, mean particle size and encapsulation efficiency data for each formulation. Data are shown as mean ± SD.  
 
FORMULATION 
PRODUCTION 
YIELD 
(%) 
MEAN SIZE 
(µm) 
ENCAPSULATION EFFICIENCY 
µg DX/mg 
MSs 
µg MEL/mg 
MSs 
µg Q10/mg 
MSs 
EE DX (%) EE MEL (%) 
EE CoQ10 
(%) 
Empty-MSs 85.97±3.46 24.72±0.79 - - - - - - 
DX-MSs 86.62±3.85 24.50±1.76 162.49±2.55 - - 97.49±1.53 - - 
MEL-MSs 86.41±1.55 27.46±0.66 - 56.52±1.34 - - 62.17±1.47 - 
CoQ10-MSs 75.15±3.23 29.97±1.81 - - 45.56±1.85 - - 95.66±3.87 
DMQ-MSs 72.99±0.60 29.04±1.89 115.86±0.62 45.80±1.86 35.71±1.53 78.20±0.42 61.83±2.51 96.42±4.12 
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3A). The amount of MEL released from MEL-loaded MSs within 24 hours (burst) 
represented 22.53 ± 0.74 % (12.73 ± 0.12 μg MEL/mg MSs) of the encapsulated drug. 
After this initial burst, a relatively rapid drug delivery occurred during the first 10 days 
(4.30 ± 3.96 μg MEL/mg MSs/day). Subsequently, the MEL release rate resulted lower 
(0.13 ± 0.15 μg MEL/mg MSs/day) from day 10 to day 30 (Fig 3B). Finally, CoQ10-
loaded MSs showed a sustained release of the CoQ10 at a rate of 0.35 μg/mg 
MSs/day during the 30-day study. No burst effect was observed (Fig. 3C).  
Release profile of the multiloaded-MSs formulation (DMQ-loaded MSs) exhibited an 
initial burst of DX of 3.78 ± 0.71% (DX 4.38± 0.80 μg DX/mg MSs), followed by a 
release rate of 0.60 ± 0.04 μg DX/mg MSs/day until day 24 and 1.20 ± 0.15 μg DX/mg 
MSs/day from day 24 to day 30. Regarding MEL release, after a burst effect of 28.27± 
3.59% (12.91± 1.12 μg MEL/mg MSs), a biphasic release occurred with a rate of 1.66± 
0.31 μg MEL/mg MSs/day for the first 14 days and 0.69 ± 0.18 μg MEL/mg MSs/day 
until day 30. Finally, DMQ-loaded MSs presented a controlled release of the CoQ10 at 
a rate of 0.63 μg Coenzyme Q10/mg MSs/day during the study (Fig. 3D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cumulative in vitro release (µg/mgMSs) of DX from DX-loaded MSs [A], MEL from MEL-loaded MSs [B], CoQ10 
from CoQ10-loaded MSs [C] and DX, MEL, CoQ10 from DMQ-loaded MSs [D] over one month. Release media: 
PBS (pH7.4) and 0.02%Na azide. 
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3.1.3. DSC measurements 
DSC scans, which provide qualitative information about the physical status of the drugs 
in each system, are provided in Figure 4. The thermograms of pure active substances 
(DX, MEL and CoQ10) displayed sharp endothermic transitions at 244, 118 and 55 ºC 
respectively, corresponding to their melting points (Fig. 4A). These peaks are also 
detected in the physical mixture (drugs plus PLGA) (Fig. 4B) whereas they decreased 
or disappeared in the loaded MSs containing the same fractions of drugs as the 
physical mixture indicating successful encapsulation (Fig. 4C and 4D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. [A] DSC curves of DX, MEL, CoQ10. [B] DSC curves of physical mixture of DX+PLGA, MEL+PLGA, CoQ10+PLGA. [C] 
DSC curves of DX-MSs, MEL-MSs, CoQ10-MSs and Empty-MSs. [D] DSC curves of DMQ-MSs and Empty-MSs. 
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3.2. DX/MEL/CoQ10-loaded MSs are neuroprotective in vitro against established 
model of excitotoxicity-mediated neurotoxicity in R28 retinal cultures.  
An in vitro model of glutamate-mediated neurotoxicity in R28 cells was used to 
evaluate the neuroprotective activity of varying concentrations of the three active 
substances (DX (50 µM, 100 µM,200 µM), MEL (250 µM, 500 µM, 750 µM), CoQ10 (1 
µM, 10 µM, 25 µM)) and vehicle controls. Data were fit in dose-response curves to 
determine the IC50 values. Figure 5 illustrates that while the treatment of cells with DX 
did not elicit a significant neuroprotective effect in this cytotoxic model (Fig. 5A), MEL 
(500 µM and 750 µM) was neuroprotective compared to control (one-way ANOVA with 
Tukey posthoc test, p = 0.0012) (Fig. 5B). Also, CoQ10 (10 µM and 25 µM) promoted a 
significant reduction in cell death induced by glutamate (one-way ANOVA with Tukey 
posthoc test, p =0.0012) (Fig. 5C). 
20 mg/mL of DMQ-loaded MSs (burst initial: 108.5 µM DX, 555.9 µM MEL and 4 µM 
CoQ10), but not non-loaded MSs, provided protection against the excitotoxic agent 
insult (glutamate) in R28 cell cultures. Treatment of R28 with the multiloaded MSs 
significantly reduced the susceptibility of these cells to glutamate-induced cytotoxicity 
(one-way ANOVA with Tukey posthoc test, p = 0.0061) (Fig.5D and 5E). 
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3.4. Multiloaded MSs formulation inhibits RGC degeneration in the Morrison's model of 
ocular hypertension.  
A well-established rodent model of experimental glaucoma was used to determine 
whether intravitreal injection of the multiloaded (DMQ) MSs had neuroprotective 
efficacy in vivo.  Peak IOP was recorded one day after OHT induction and IOP 
elevation was maintained for at least 7 days after induction in all groups (Table 3 & 
Fig.6F). No significant change in IOP was observed in contralateral eyes. Intravitreal 
administration of the different treatments (empty-MSs, DMQ-MSs and physical mixture 
of MSs) had no effect on IOP profiles compared to OHT only eyes, suggesting that 
 
Figure 5. [A-C] MEL (500 µM and 750 µM) and CoQ10 (10 µM and 25 µM) but not DX resulted  neuroprotective compared to 
control against glutamate-mediated neurotoxicity (one-way ANOVA with Tukey posthoc test, p = 0.0012 and p =0.0012 
respectively). [D,E] Neuroprotective effect of DMQ-loaded MSs against cytotoxic insult in R28 cell  cultures. Trea tment with 
DMQ-loaded MSs (20 mg MSs/mL) but not equivalent concentrations of non-loaded MSs only significantly (one-way ANOVA, p 
= 0.0061) reduced the susceptibil ity of these cells to glutamate-induced cytotoxicity. 
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treatments did not affect IOP and that any neuroprotective effects observed were IOP 
independent.
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Table 3 
 Mean IOP measurements and integral IOP (± SD) for each treatment group in this study. 
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RGC loss due to increase of IOP was determined histologically by whole-retinal flat 
mounts immunolabeled with anti-Brn3a antibody (as example: Fig. 6Ai Naïve whole 
retina illustration). Figures from 6Aii to 6E show the RGC distribution from sections of 
Naive [Aii], OHT only [B], Empty MSs[C], Mixture MSs [D] and DMQ-MSs [E] from 
equivalent distances from the ONH in the retinal whole-mounts. Quantification of whole 
RGC populations was completed using an automated script as previously described 
[41]. Linear regression analysis (R version 3.3.1, eq. 2) was used to evaluate the 
efficacy of different treatments in the rodent OHT model with RGC density (cells/mm2) 
as the dependent variable (y) and treatment group as the independent variables (βτ) 
with categories OHT only (intercept, β0), Naïve retina, Drug loaded MSs, empty MSs 
and mixtures comprising three single-drug loaded MSs. The results of the regression 
analysis indicated the treatment group predictors explained 58.4% of the variance in 
RGC density (R2 =.50, F(4,19)=6.677, p=0.01565). Compared to OHT only group (β0 = 
1253 ± 76 cells/mm2, p < 0.001) It was found that application of drug loaded MSs 
significantly preserved RGC density (βτ1 = 287 ± 108 cells/mm
2, *p = 0.0155), to a 
comparable extent as the naïve retina control group (βτ2= 280 ± 98 cells/mm
2, *p = 
0.0104). Administration of drug empty MSs (βτ3 = 4 ± 102 cells/mm
2, p = 0.97) or 
combinations of single-drug loaded MSs (βτ4 = -101 ± 102 cells/mm2, p = 0.34) with a 
residual standard error (ε) of 152 cells/mm2 with 19 DF. Administration of drug empty 
MSs (βτ3 = 4 ± 102 cells/mm
2, p = 0.97) or combinations of single-drug loaded MSs (βτ4 
= -101 ± 102 cells/mm2, p = 0.34) had no significant preserving effect on RGC 
population with a residual standard error (ε) of 152 cells/mm2 with 19 DF (Figure 5G). 
𝑦 =  𝛽0 +  𝛽𝜏𝑥 +  𝜀      [eq. 2] 
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4. Discussion 
Glaucoma is a worldwide leading cause of irreversible vision loss[46]. Although the 
exact mechanism of glaucoma pathology is debatable,[47] a hallmark of this disease is 
RGC degeneration that leads to vision deficit or loss[48]. Thus, there is an imperative 
need to develop RGC-targeted therapies that can be conveniently delivered providing 
via a long-term sustained drug release [49]. As the RGC degeneration occurs by 
different pathways, the present work suggests for the first time a beneficial role of a 
combination of three different neuroprotectants with anti-inflammatory and antioxidant 
 
Figure 6. Intravitreal DMQ-MSs treatment but not MSs Mixtures preserved RGC density in a well -established rodent 
model of Ocular Hypertension. Each red box is ~1 mm
2
: [Ai] Naïve whole retina i l lustration [Aii] Il lustration of RGC 
distribution from sections of Naive, [B] OHT only, [C] Empty MSs [D] Mixture MSs [E] DMQ-MSs treated retinal whole-
mounts taken from equivalent distances from the ONH. [F] Treatment of eyes with intravitreal administration of 
Empty-MSs, DMQ-MSs or the mixture of MSs did not significantly alter the IOP profiles compared on OHT induction 
(two-way repeated measures ANOVA with Bonferroni post-test versus OHT model, p > 0.05) suggesting any 
neuroprotective activity of treatments was a result of IOP independent effects. Results are mean ± SD. [G] Whole 
retinal RGC density measurements indicate that while OHT induction (β0 = 1253 ± 76 cells/mm2, p < 0.001), empty 
MSs (βτ3 = 4 ± 102 cells/mm2, p = 0.97)  or combinations of single-drug loaded MSs (βτ4 = -101 ± 102 cells/mm2, p  = 
0.34) caused a significant reduction in RGC density, RGC loss was preserved by an intravitreal administration of DMQ -
MSs (βτ1 = 287 ± 108 cells/mm2, *p = 0.0155), to a comparable extent as the naïve retina control group (βτ2= 280 ± 
98 cells/mm2, *p = 0.0104).  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
27 
 
activity (DX, MEL, and CoQ10) formulated as a multi-loaded microparticulate PLGA 
system (DMQ-MSs) in reducing RGC loss in an experimental glaucomatous model. 
This multi-IODDS resulted more effective than the administration of a mixture of MSs 
loaded with the three drugs separately (MSsmix). As far as we are aware, this is the 
first co-delivery study for incorporating three neuroprotective agents into a single carrier 
system for the posterior segment of the eye. 
High production efficiency yields (> 72%) and drug loading efficiencies (> 61%) were 
achieved in each case. DX encapsulation efficiency slightly decreased (~20%) in the 
multiloaded MSs compared to the single one drug formulation suggesting some 
competition for drug loading sites.  The competition might be solved by the addition of 
co-solvents like ethanol into the inner polymeric solution. This technological strategy 
has been already reported by other authors [50-52]. However, since DMQ-MSs 
formulation contains three different drugs, this technology-based improvement would 
require optimization procedures. 
 Multi-loaded and single loaded MSs exhibited a homogeneous particle size (20 – 38 
µm), with spherical morphology and were found to be suitable for its injection as a 
suspension through needles typically used for intravitreal administration (25G-32G) [53, 
54]. Scanning electron microscopy images of CoQ10 loaded MSs and multi loaded-
MSs revealed the presence of pores on the particles’ rough surfaces. This fact has 
been previously explained as consequence of the rapid removal of organic solvent 
during elaboration procedure and to the encapsulation process characteristic of this 
poor soluble drug [55, 56]. According to the images observed by transmission electron 
microscopy, the inner structure of the multi loaded-MSs correspond to a combination of 
the different entrapped drugs. Thus, a mixture of DX solid forms and small and large 
pores like those observed in fractured MSs of MEL and CoQ10 can be observed in the 
multi-loaded formulation (DMQ-MSs).  The appearance of inner pores larger than the 
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ones on the surface lies on the different solidification rates occurring during the 
processes of microsphere’s formation and maturation[57].  
The inner structure is determined by the solidification rate of the polymer during the 
microparticle preparation process. A high polymer concentration, as the one used in 
the present work, involves a faster polymeric precipitation resulting in a matrix dense 
and a relatively porous inside. The nature of the entrapped drugs is also a critical factor 
since release is longer with decreasing water solubility of the drug [52]. Therefore, the 
morphology of the microparticles, as well as the low solubility of the active compounds 
(DX, MEL, CoQ10), contributed to high encapsulation efficiencies and a prolonged 
release profile. 
Additional characterization of MSs formulations was achieved using DSC. As expected, 
characteristic transitions of free drugs were present when these agents were assessed 
as physical mixtures with PLGA. DMQ-MSs thermogram, however, lost or reduced 
these characteristic peaks, providing evidence of their association with MSs polymeric 
matrix. This is further supported by the observation of a slight decrease in PLGA 
transition temperature in all formulations, probably due to the plasticiser effect of the 
small active molecules present and also to the micrometric size and high surface area 
of the particles [58]. Furthermore, the presence of the endothermic peak of DX in DX-
MSs formulation could be attributed to the presence of DX crystals embedded in the 
MSs matrix, an expected result in accordance with the TEM images of these fractured 
microspheres. In addition, the disappearance of the CoQ10 endotherm in the 
thermogram of MSs containing CoQ10 regarding to the physical mixture, suggests the 
dissolution of CoQ10 in the polymeric organic solution during the production procedure 
[58]. Finally, contrary to the physical mixture (MEL plus PLGA), no free drug peaks 
were identified in the thermograms of MEL-MSs. This thermotropic variation would 
suggest that MEL was dispersed at molecular level inside the polymeric cavities, which 
might be attributed to the amphiphilic properties of the melatonin [59, 60] and could 
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explain the TEM pictures observed. DSC thermograms from DMQ-MSs revealed the 
presence of the melting peaks of DX and MEL, which might suggest the presence of 
part of these drugs in its solid form in the multi-loaded MSs formulation. 
Multi-loaded microspheres provided simultaneous controlled co-delivery of the three 
therapeutics agents. The release rate of CoQ10 and DX from DMQ-MSs resulted in 
two (0.63 µg/mg MSs/day) and around three-fold (0.60 µg/mg MSs/day) higher 
respectively compared to single loaded particles. These findings could be explained by 
the lower polymer/mg MSs ratio in the multi-loaded particles. In contrast, the delivery of 
MEL resulted in significantly slower release rates (1.66 µg/mg MSs/day) than single 
loaded microspheres. A possible explanation for this is that the presence of very poorly 
soluble substances (such as CoQ10) can modulate the release of other more soluble 
compounds from a combined formulation [61]. Furthermore, the presence of MEL 
crystals in DMQ-MSs suggested by DSC studies may explain the release rate 
reduction; future studies will seek to confirm these hypotheses. 
The neuroprotective activity of DMQ-MSs formulations were assessed using an in vitro 
glutamate-mediated neurotoxicity model in an immortalised neuronal cell line (R28). 
Results suggest that CoQ10 and MEL treatments were significantly protective against 
this insult. Glutamate mediated neurotoxicity in the retina is considered as one of the 
factors contributing to glaucoma pathogenesis [47, 62-64]. Neuronal vulnerability to 
glutamate has been attributed to mitochondrial membrane depolarization triggering a 
profound drop of intracellular ATP level and ROS generation [65, 66]. CoQ10 may help 
to the maintain mitochondrial membrane potential and so inhibit the opening of the 
mitochondrial permeability transition pore (PTP) which may lead to apoptosis induction 
[67]. Furthermore, it has been suggested that CoQ10 may also contribute to the 
reduction in expression of the glutamate binding receptor (N-methyl-D-aspartate 
receptor) subunits (NR1 and NR2A) in a mouse model of glaucoma [68]. We postulate 
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that these protective activities of CoQ10 work in conjunction with its well documented 
antioxidant activity [35] to protect R28 cells against glutamate-induced cell death.   
The ability of MEL to inhibit glutamate neurotoxicity has been previously attributed to 
the reduction of oxidative stress via multiple processes [69]. MEL has been reported to 
act both as a direct free radical scavenger [70], and as an indirect antioxidant through 
the stimulation of antioxidant enzymes such as Superoxide dismutase [71]. MEL also 
promotes the synthesis of glutathione, an essential intracellular antioxidant [72], and it 
is able to increase the efficiency of the mitochondrial electron transport chain (ETC) 
thereby lowering electron leakage and reducing free radical generation [73, 74].  This 
study provides additional evidence to suggest that MEL is protective against glutamate-
induced neurotoxicity and these findings are in agreement with those obtained by other 
groups [68, 75]. 
The in vitro experiments demonstrated no benefit of dexamethasone treatment in 
preserving cell function in vitro. However, the in vitro system does not model the full in 
vivo environment with multiple cell types at different levels.  Our in vitro model 
consisted only of R28 cells and no microglia or astrocytes. We were therefore not 
expecting a neuroprotective effect with little expectation even for an immunemodulatory 
effect either, but wanted to be sure there was no toxicity. In any case inflammation 
events occurring within the in vivo environment of retinal degenerative diseases as we 
described in the introduction. 
The DMQ-MSs formulation was assessed in vivo using a well-established rodent model 
of ocular hypertension (OHT) [76-78]. Intravitreal administration of 0.1 mg DMQ-MSs 
was compared to a physical mixture of single drug loaded MSs (0.23 mg) containing 
the same amount of active drug substances, empty MSs, an OHT only (untreated) 
group and naïve controls (No OHT or treatment). Three weeks after OHT induction, 
RGCs survival was quantified histologically from retinal whole mounts using Brn3a+ 
labelling as previously described [41]. Intravitreal administration of DMQ-MSs was 
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found to significantly promote RGCs survival compared to administration of empty 
MSs. Although the amount of drug release is low, particularly in the case of Coq10, the 
simultaneous delivery of the three drugs resulted in a significant neuroprotective 
activity. The efficacy of low amounts released from PLGA microsystems loaded with 
neuroprotective agents has been already reported [61, 79-81]. 
Interestingly, administration of a mixture of MSs loaded with the three drugs separately 
(MSsmix) was found to be mildly neurotoxic. This may be related to the MSsmix 
formulations requiring a higher concentration of MSs particles than DMQ-MSs (0.23 mg 
vs 0.1 mg respectively), which may contribute to retinal toxicity. In support of this 
hypothesis, we previously reported that intravitreal injection of 0.5 mg of PLGA but not 
0.1 mg PLGA induced retinal stress and neuronal cell dysfunctions in rats [23].  
In the present work, a multi-therapy approach comprising DX, MEL and CoQ10 was 
chosen in order to target multiple pathways of neuronal degeneration simultaneously 
[12]. 
Corticosteroids has been suggested to induce neuroprotection by indirectly modulating 
microglia activity [82]. Furthermore, corticosteroid anti-inflammatory and 
immunosuppressive effects are thought to modulate the production of neurotoxic 
substances by microglial and the rate of phagocytosis of apoptotic neurons. [83] The 
neuroprotective effects of melatonin and coenzyme Q10 in the retina are based on their 
well-documented antioxidant activity and mitochondrial protection, which could prevent 
development and progression of neurodegeneration [29, 84].  
MEL has demonstrated to protect retinal ganglion cells against apoptosis in a in vivo 
rodent model of nitric oxide induced retinal injury [30] and after acute injury intraorbital 
optic nerve transection or hypoxia [85, 86]. Interestedly, the protective effect of MEL is 
not only confined to neurons, as it may also elicit neuroprotection by acting on retinal 
glia, which is increasingly recognised to play an important role in the pathogenic 
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cellular processes of glaucoma [87]. Recently, we have also found that controlled 
delivery of MEL after a single intravitreal injection of MSs in combination with a 
neurotrophic factor (glial cell-line-derived neurotrophic factor, GDNF) promoted a 
rescue of the photoreceptors in rho (-/-) mice[24].  
The neuroprotective effect of CoQ10 in RGCs has previously been suggested through 
the prevention of glutamate-induced apoptosis or inhibition of mitochondrial 
depolarization after topical administration in an IOP-induced transient ischemia rat 
model or in a UV-induced rat model of retinal damage respectively [67, 88]. In fact, 
topical instillation of this mitochondrial-targeted antioxidant was found to promote RGC 
neuroprotection in the same rodent model of ocular hypertension employed in the 
current study [36]. The mechanism of neuroprotection was attributed to the decrease of 
glutamate excitotoxicity and oxidative stress that preserve mtDNA content and 
Tfam/OXPHOS complex IV protein expression in the retina [68]. Similarly to MEL, the 
neuroprotective activity of CoQ10 has also been attributed to mitochondrial mediated 
modulation of retinal glial activation [89, 90]. 
Although several fixed combination therapies of antihypertensive drugs are currently in 
clinical practice, an equivalent neuroprotective combination therapy has not yet been 
clinically translated [91-93]. In summary, this paper presents a novel neuroprotective 
combination therapy combining an anti-inflammatory drug (DX) with two antioxidants 
(MEL and CoQ10). These drugs were delivered from a PLGA polymeric microcarrier 
(DMQ-MSs) which resulted in significant neuroprotection in a rodent model of RGC 
loss (ocular hypertension). Furthermore, the amount of polymer resulted lower than the 
one necessary for the physical mixture of microspheres resulting in a good tolerance of 
the formulation. Although the neuroprotective efficacy of other drug delivery systems 
has previously been reported [94-97], to the authors’ knowledge, this is the first study 
to present an effective intraocular drug delivery system (IODDS) loaded with three drug 
cargo for the treatment of retinal degeneration. 
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Conclusion 
This study presents a novel, effective and well-tolerated intraocular drug delivery 
system (IODDS) comprising PLGA polymeric microparticles for the co-delivery of three 
neuroprotective substances. This novel multi-therapy strategy allowed the co-
incorporation of different drugs into a single microcarrier reducing the amount of 
biomaterial (PLGA) required for intraocular administration compared to equivalent 
dosing of single drug loaded formulations, so reducing the risk of PLGA associated 
retinal stress. Moreover, this IODDS provided the simultaneous release of the three 
active agents in a controlled fashion. In vivo efficacy studies revealed that the multi 
loaded IODDS could not only preserve the RGCs from death, but also resulted in a 
higher efficacy than the physical mixture of MSs. These findings indicate that 
combination therapy using multi-loaded MSs may be a promising neuroprotective 
strategy for the treatment of multifactorial retinal diseases such as glaucoma. 
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Table 1 
Suspensions of administered MSs  
 
 DMQ-loaded MSs 
Physical Mixture of MSs 
Empty-MSs 
DX-MSs  MEL-MSs  CoQ10-MSs  
AMOUNT OF MSs (mg) 
 0.071 0.082 0.08  
0.1 
 
0.233 
 
0.233 
DOSES (µg drug) 
DX / MEL /CoQ10 
11.5 / 4.6 / 3.6 
      DX                   MEL                CoQ10 
     11.5                   4.6                    3.6 
- 
VOL. INYECTED (µL) 4 4 4 
 MSs suspension (w/v) % 2.5 5.825 5.825 
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Table 2 
Production yield, mean particle size and encapsulation efficiency data for each formulation. Data are 
shown as mean ± SD. 
 
 
 
FORMULATI
ON 
PRODUCTI
ON YIELD 
(%) 
MEAN 
SIZE 
(µm) 
ENCAPSULATION EFFICIENCY 
µg DX/mg 
MSs 
µg 
MEL/mg 
MSs 
µg 
Q10/mg 
MSs 
EE DX 
(%) 
EE MEL 
(%) 
EE 
CoQ10 
(%) 
Empty-MSs 85.97±3.46 
24.72±0.
79 
- - - - - - 
DX-MSs 86.62±3.85 
24.50±1.
76 
162.49±2.
55 
- - 
97.49±1.
53 
- - 
MEL-MSs 86.41±1.55 
27.46±0.
66 
- 
56.52±1.
34 
- - 
62.17±1.
47 
- 
CoQ10-MSs 75.15±3.23 
29.97±1.
81 
- - 
45.56±1.
85 
- - 
95.66±3.
87 
DMQ-MSs 72.99±0.60 
29.04±1.
89 
115.86±0.
62 
45.80±1.
86 
35.71±1.
53 
78.20±0.
42 
61.83±2.
51 
96.42±4.
12 
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Table 3 
 Mean IOP measurements and integral IOP (± SD) for each treatment group in this study. 
 
 
Time post OHT induction 
(days) 
 
OHT 
only 
OHT 
(Co-eye) 
OHT+Empty-MSs  
OHT+Empty-MSs  
(co-eye) 
OHT+DMQ-MSs  
OHT+DMQ-MSs  
(co-eye) 
OHT+Mixture of MSs  
OHT+Mixture of MSs     
(co-eye) 
0 10.03 
(0.40) 
 
10.02 
(0.13) 
10.18 
(0.16) 
10.34 
(0.22) 
10.40 
(0.61) 
10.30 
(0.32) 
10.30 
(0.34) 
10.00 
(0.47) 
1 25.46 
(3.11) 
 
10.95 
(1.29) 
22.70 
(1.43) 
10.10 
(0.41) 
25.70 
(5.82) 
10.25 
(0.65) 
24.56 
(3.57) 
10.66 
(0.72) 
7 19.94 
(3.44) 
 
10.48 
(0.95) 
20.32 
(2.73) 
10.28 
(0.60) 
20.30 
(3.64) 
10.43 
(1.06) 
18.02 
(0.84) 
10.22 
(0.63) 
14 14.20 
(3.07) 
 
11.78 
(1.14) 
14.88 
(1.29) 
10.78 
(0.53) 
14.60 
(2.56) 
10.85 
(1.00) 
15.92 
(3.06) 
11.44 
(0.63) 
21 12.34 
(1.36) 
 
10.80 
(0.79) 
13.01 
(2.19) 
10.56 
(0.70) 
12.45 
(0.10) 
10.95 
(1.40) 
15.62 
(3.37) 
11.24 
(1.17) 
Integra l  IOP 
(mmHg/day) 
366.34 
(23.65) 
225.56 
(16.36) 
366.34 
(32.24) 
219.8 
(5.25) 
372.9 
(45.06) 
223.1 
(16.17) 
374.36 
(24.82) 
228.18 
(4.60) 
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